MangoRx Launches 'PRIME' By MangoRx, Powered By Kyzatrex FDA Approved Oral Testosterone Replacement Therapy Treatment
Portfolio Pulse from Benzinga Newsdesk
Mangoceuticals, Inc. (NASDAQ:MGRX), also known as MangoRx, announced the launch of 'PRIME' by MangoRx, an FDA-approved oral testosterone replacement therapy (TRT). This product aims to target men currently on TRT or experiencing low testosterone symptoms, leveraging MangoRx's telehealth platform for distribution. The company plans to market PRIME to a significant addressable market, including those averse to injectable TRT, by utilizing social media influencers, celebrities, and athletes. PRIME's launch represents a strategic expansion into a new vertical with substantial market potential.
March 12, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mangoceuticals, Inc. (MGRX) launches 'PRIME', an oral testosterone replacement therapy, aiming to capture a significant market share in the TRT sector through its telehealth platform.
The launch of 'PRIME' by MangoRx introduces a novel product in the TRT market, potentially attracting a large customer base due to its non-invasive nature and convenience. The strategic marketing plan involving social media influencers and celebrities could significantly enhance brand visibility and adoption, driving up demand. Given the size of the target market and the innovative approach to distribution and marketing, this launch is likely to have a positive short-term impact on MGRX's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100